Changing the game of drug development with the Intabio ZT system

Oct 4, 2023 | Biopharma, Blogs, ZenoTOF | 0 comments

Read time: 5minutes

What better to learn how a new technology like icIEF-UV/MS is advancing drug development than hearing from the labs that are using it?

Kristen Nields, Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson sat down with me for a quick Q&A to discuss:

  • Common bottlenecks in the drug development pipeline
  • The importance of charge variant analysis for Janssen
  • The benefits she is seeing using a novel integrated workflow for peak ID of charge variants

Question: What does your group do at Janssen?

Answer: In the Cell Engineering and Analytical Analysis group, we assist in the development of new molecules for different therapeutic areas. Once a biotherapeutic is deemed viable, it’s handed over to us for in-depth characterization. We look at disulphide bond reductions, biophysical properties (such as charge heterogeneity), mass analysis, size exclusion and so on before going through cell line selection. We then take the data, along with bioreactor data (such as titer, cell density and cell growth), and we pick a top clone.

From there, the top clone goes into a master cell bank for the production of clinical material, which allows the development team to create efficient and scalable upstream and downstream processes for manufacturing, part of thisinvolves examining the clone’s charge heterogeneity profile.

Question: Can you explain the importance of understanding the charge profile at this point?

Answer: During the manufacturing process, charge heterogeneity of the protein therapeutics can occur due to enzymatic cleavage and chemical post-translational modifications (PTM). PTMs such as deamidation, glycation and sialylation, affect a proteins charge. It is important to understand a protein’s charge profile and how to control it before upstream process development. The levers you pull to increase titer can impact charge heterogeneity, which then becomes locked in at harvest downstream and cannot be removed. In short, charge variant analysis is important for establishing a valid release method.

Question: What are common bottlenecks in the current workflow?

Answer: The major bottleneck is method validation for imaged capillary isoelectric focusing (icIEF), which is the primary technique used for charge variant analysis. Why? Because the smallest process changes can alter the acidic or basic isoforms of the protein, affecting the peak areas and rendering the initial assay invalid. When this happens, a comprehensive investigation under good manufacturing practice guidance is required.

Determining the identity of the acidic peak using icIEF alone is challenging, and it can take 1 or 2 months to reach purification at the required levels for the progression of clinical testing. This process leads to significant downtime, product holds, extensive quality control efforts and the potential need to engage with regulatory agencies to resolve the issue.

Question: How does the Intabio ZT system address these challenges?

Answer: On the front end, it’s a typical icIEF system, so all the front-end components stay the same. This means existing validated icIEF methods can be directly applied to this system, so you will achieve the same charge profile. And that’s crucial because introducing new technologies for products that are in phase III development or already approved can create significant regulatory challenges, including side-by-side testing for up to 5 years to demonstrate comparability.

Once the sample comes off the microfluidic icIEF chip, it enters the mass spectrometer, where you can analyze the acidic and basic peaks in real-time and identify each peak.

This new integrated workflow is a real game changer, serving as an intact protein multi-attribute methodology in the field of mass analysis. The Intabio ZT system gives you a real-time online icIEF-UV/ MS profile, which allows us to investigate the composition of each peak. This results in fewer investigations and faster identification compared to the alternative approach, which required fractionation and subsequent peptide mapping in the hopes of finding agreement with the icIEF-UV profile.

Question: What does this “game changer” mean for drug development?

Answer: For years, we biochemists and chemists have wanted to know what’s under those peaks, and now we can find out – in real time – and that’s exciting!

Ultimately, the Intabio ZT system could help ensure faster biopharmaceutical product characterization and process development – a huge bottleneck in biopharma – to reduce drug development timelines.

Looking for more information on this technology?

SCIEX released the Intabio ZT system at ASMS 2023.  Visit the Intabio ZT system product page to watch the product video, and gain additional insight into how you can better understand the charge heterogeneity profile of your molecule at the intact level.

Kristen is also a guest on the Rewriting the Rules Vodcast where she joins my colleague Kerstin Pohl and I to discuss the Intabio ZT system workflow, and how to incorporate new workflows into an established process.

Additional resources available:
Charge Heterogeneity Analysis
Intact Protein Analysis
ADC Analysis

Beyond mRNA: how advances in analytical techniques are enabling a revolution in the RNA drug landscape

Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs. Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified nucleotides—are non-replicating. The third type is self-replicating RNA (srRNA), which is based on an engineered viral genome but devoid of viral structural protein genes. Its self-replicating ability makes srRNA a promising tool for new therapeutic drugs.

The whys behind the dos and don’ts of oligonucleotide analysis

We know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.

Overcoming N-nitrosamine analysis challenges with mass spectrometry and chromatography solutions

N-nitrosamine analysis has raised significant concerns in the pharmaceutical industry since 2018, when these potential carcinogens were found in several angiotensin II receptor blockers (sartans). Subsequent discoveries in ranitidine and some slow-release metformin medications prompted widespread product recalls. The industry has implemented stricter manufacturing requirements and intensified efforts to evaluate and control N-nitrosamine contamination. To meet stringent regulatory requirements, it is essential to develop effective chromatography and mass spectrometry (MS) methods for N-nitrosamine analysis. This blog addresses the challenges associated with detecting N-nitrosodimethylamine (NDMA) in metformin drug products.

Posted by

Roxana has over 15 years of experience in sales and marketing roles in the MS community. As Senior Global Marketing Manager for protein therapeutics at SCIEX, she specializes in communicating innovations in MS and CE-based workflows to the biopharma community.


Submit a Comment